Loading...
Docoh

Bellicum Pharmaceuticals (BLCM)

Utility
Methods for Controlled Elimination of Therapeutic Cells
28 Apr 22
The technology relates in part to methods for controlling elimination of therapeutic cells, for example, cells that express a chimeric antigen receptor.
David M. Spencer, Aaron Edward Foster, Joseph Henri Bayle, Kevin M. Slawin, Matthew R. Collinson-Pautz
Filed: 9 Jun 21
Utility
Psca Car-t Cells
3 Mar 22
The technology relates generally to the field of immunology and relates in part to T cell compositions and methods for treating diseases and disorders associated with the presence of tumor cells that express prostate stem cell antigen.
Paul WOODARD, Aaron Edward FOSTER, David Michael SPENCER, Olivia GARDNER, William GROSSMAN, Matthew Robert COLLINSON-PAUTZ, Annemarie MOSELEY
Filed: 12 Dec 19
Utility
T Cells with Suicide Switch
6 Jan 22
We disclose various improvements for compositions of genetically-modified T cells which include a suicide switch.
Xiaoou Linnette Zhou, Joanne Louise Shaw, Aaron Edward Foster, Madhavi Anumula, Matthew R. Collinson-Pautz
Filed: 29 Oct 19
Utility
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
11 Nov 21
The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.
David Spencer, Aaron Edward Foster, Kevin Slawin
Filed: 7 Dec 20
Utility
Methods to Augment or Alter Signal Transduction
20 May 21
The technology relates generally to the field of immunology and relates in part to compositions and methods for activating cells, including, for example T cells that express chimeric antigen receptors or recombinant TCRs, and reducing cytotoxicity, using chimeric polypeptides including MyD88 and signaling domains of receptor mediators of costimulation.
Joseph Henri Bayle, Wei-Chun Chang, Aaron Edward Foster, David Michael Spencer
Filed: 8 May 18
Utility
Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
2 Mar 21
The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides.
Aaron Edward Foster, David Spencer, Matthew Robert Collinson-Pautz, Kevin Slawin
Filed: 13 Feb 15
Utility
Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides
16 Feb 21
The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.
David Spencer, Aaron Edward Foster, Kevin Slawin
Filed: 11 Feb 20
Utility
Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
12 Jan 21
The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.
David Spencer, Aaron Edward Foster, Kevin Slawin
Filed: 1 Sep 15
Utility
Methods for Enhancing and Maintaining Car-t Cell Efficacy
4 Nov 20
The technology relates generally to the field of immunology and relates in part to compositions and methods for activating T cells and other cells resulting in an immune response against a target antigen.
Aaron Edward Foster, David Michael Spencer
Filed: 6 Dec 18
Utility
Multimeric piperidine derivatives
30 Sep 20
Steven Toler, Slawomir Szymanski
Filed: 18 Dec 18
Utility
Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides
29 Jul 20
The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.
David Spencer, Aaron Edward Foster, Kevin Slawin
Filed: 10 Feb 20
Utility
Methods for Inducing Partial Apoptosis Using Caspase Polypeptides
22 Jul 20
The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide.
Kevin Slawin, David Michael Spencer, Aaron Edward Foster
Filed: 2 Jan 20
Utility
Methods for inducing partial apoptosis using caspase polypeptides
6 Jan 20
The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide.
Kevin Slawin, David Spencer, Aaron Edward Foster
Filed: 4 Feb 18
  • 1
Patents are sorted by USPTO publication date, most recent first